InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
July 06 2021 - 7:05AM
Business Wire
Calls for All Stockholders to Vote and to Vote
in Favor of the Proxy Proposals
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research
and clinical-stage biomaterials and biotechnology company with a
focus on the treatment of spinal cord injuries, today reminded
stockholders that their virtual Annual Meeting of Stockholders is
scheduled for Friday, July 16, 2021 at 11 a.m., ET and called on
stockholders to vote to ensure that a quorum is present to hold the
meeting and that the Company’s proxy proposals are passed.
Stockholders holding common stock at the close of business on
Monday, May 17th, 2021 are entitled to vote at the meeting, even if
they have subsequently sold their shares. Stockholders who have
previously submitted their proxy or otherwise voted and who do not
want to change their vote need not take any action.
InVivo is also asking stockholders to follow their Board of
Directors’ recommendation to vote FOR all proposals,
including the election of directors, increase in authorized shares
of common stock, authorization of shares of “blank-check” preferred
stock, an amendment to the 2015 Equity Incentive Plan and
ratification of independent registered public accounting firm. The
Board of Directors believes that Proposal #2, the increase in
authorized common shares, will enable InVivo to engage in capital
raising transactions and other strategic transactions involving the
issuance of equity securities. Although InVivo has no specific
current plans to issue shares of common stock, it has limited
capital, and to execute on its business plan and remain viable as a
going concern, it must have the flexibility to engage in capital
raising transactions until it is able to generate sufficient
revenue and cash flow. Increasing the number of authorized shares
of common stock will enable InVivo to issue common stock or
securities convertible or exercisable into common stock to
investors and other strategic partners.
For questions relating to the voting of shares or to request
additional or misplaced proxy voting materials, please contact the
Company’s proxy solicitors, Morrow Sodali LLC, at (877) 787-9239
(stockholders), or (203) 658-9400 (banks and brokerage firms).
A copy of the Company's proxy statement as previously filed with
the SEC is available at no charge on the SEC website at
www.sec.gov. In addition, copies of the proxy statement and other
documents may be obtained free of charge by accessing the Company's
website at www.invivotherapeutics.com or by contacting the
Company's Corporate Secretary at (617) 710-1233 or by mail to
Corporate Secretary, InVivo Therapeutics, One Kendall Square,
Building 1400 West, Floor 4, Cambridge, MA 02139.
YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY!
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology Company with a focus
on treatment of spinal cord injuries. The Company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. These statements
can be identified by words such as “believe,” “anticipate,”
“intend,” “estimate,” “will,” “may,” “should,” “expect” and similar
expressions, and include statements about the impact of the proxy
proposals on the Company’s operations. Any forward-looking
statements contained herein are based on current expectations and
are subject to a number of risks and uncertainties. Factors that
could cause actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to successfully
enroll additional patients; the impact of the COVID-19 pandemic on
the Company’s operations, including its clinical trials; the timing
of the Institutional Review Board process; the Company’s ability to
obtain FDA approval to commercialize its products; the Company’s
ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company’s
products and technology in connection with spinal cord injuries;
the availability of substantial additional funding for the Company
to continue its operations and to conduct research and development,
clinical studies and future product commercialization; and general
economic and market conditions and other factors discussed in the
“Risk Factors” section of the Company’s Quarterly Report on Form
10-Q for the quarter ended March 31, 2021, and its other filings
with the SEC, including the Company’s Form 10-Qs and current
reports on Form 8-K. The Company does not undertake to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210706005048/en/
Investor Contact: Bret Shapiro, Managing Partner CORE IR
brets@coreir.com (516) 222-2560 Media Contact Gina Nugent
Ten Bridge Communications gina@tenbridgecommunications.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Apr 2024 to May 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From May 2023 to May 2024